4D pharma Joins Landmark Parkinson s Progression Markers Initiative A landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments 4D pharma will play an important role as PPMI considers the microbiome as an area of focus Leeds, UK, December l8, 2020 , - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it has joined the Parkinson s Progression Markers Initiative (PPMI) as an industry partner. PPMI is a landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments.